Business
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.\n\n\nSTATEN ISLAND, N.Y., Aug. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (\"Acurx\" or the \"Company\"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the Emerging Growth Conference as follows:\nDate:\nWednesday, August 18, 2021\nTime:\n11:15 a.m. Eastern Time\nWebcast: \nhttps://goto.webcasts.com/starthere.jsp?ei=1486517&tp_key=3bd9735fe4&sti=acxp\nThis live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci. As time permits, Mr. Luci may be able to respond to questions from participants.\nThe presentations will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company's website at www.acurxpharmaceuticals.com, under the Investors section.\nAbout Acurx Pharmaceuticals, Inc.\nAcurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D preclinical pipeline includes antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP). \nTo learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com. \nInvestor Contact:Acurx Pharmaceuticals, Inc.David P. Luci, President & CEOTel: 917-533-1469Email: [email protected]\n View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-august-18-2021-301353864.html\nSOURCE Acurx Pharmaceuticals, Inc.","length":6036,"tagName":"div"}]